SCHEDULE 13D: Royalty Pharma CEO Pablo Legorreta Significantly Increases Beneficial Ownership to Nearly 20% Following Strategic Transaction

Royalty Pharma plc's CEO and Chairman, Pablo Legorreta, along with Legorreta Investments, LLC, have disclosed a substantial increase in their beneficial ownership of the company's Class A ordinary shares, reaching 19.74% and 8.14% respectively, primarily due to a strategic acquisition transaction.

Summary

• Pablo Legorreta and Legorreta Investments, LLC, jointly filed a Schedule 13D, reporting their beneficial ownership in Royalty Pharma plc.
• Mr. Legorreta now beneficially owns an aggregate of 103,112,796 shares, representing 19.74% of the Class A ordinary shares.
• Legorreta Investments, LLC, beneficially owns 37,535,019 shares, representing 8.14% of the Class A ordinary shares.
• The significant increase in ownership stems primarily from a transaction on May 16, 2025, where Royalty Pharma Holdings Ltd. (a subsidiary of the Issuer) acquired all equity interests of RP LLC from various sellers, including Pablo Legorreta.
• As part of this transaction, Mr. Legorreta received 13,356,742 Class B Shares of the Issuer and 13,356,742 Class E Shares, with Class E Shares subject to a five-year vesting schedule and forfeiture conditions.
• Mr. Legorreta also received 530,348 Class A Shares on May 16, 2025, from the dissolution of the RP Management Equity Incentive Plan Trust, and 288,352 Class A Shares on May 8, 2025, from the settlement of Equity Performance Awards.
• The reported beneficial ownership includes Class A Shares, Class B Shares, and RPH Exchangeable Securities, which are convertible into Class A Shares.
• Mr. Legorreta's beneficial ownership includes shares held directly, through family investment vehicles, and shares over which he has voting power but not dispositive power (e.g., 11,173,524 Class B and Class E shares held by RP MIP (Cayman), LP).
• Certain Reporting Persons have pledged interests exchangeable for 15,850,000 Class A Shares to secure a loan, subject to the Issuer's Policy Restricting Pledging.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The filing indicates a significant increase in beneficial ownership by the CEO and Chairman, Pablo Legorreta, which generally signals strong insider confidence and long-term commitment. While there's a mention of pledged shares, it's noted as being subject to company policy, mitigating immediate concern. The transaction itself appears to be a strategic consolidation.

Positives

• Increased beneficial ownership by CEO Pablo Legorreta signals strong insider confidence in the company's long-term prospects.
• The acquisition of RP LLC by Royalty Pharma Holdings Ltd. consolidates interests, potentially streamlining operations and aligning incentives.
• The transaction structure, involving Class B and Class E shares with vesting conditions, aligns management's long-term interests with shareholder value creation.

Negatives

• The pledging of 15,850,000 Class A shares as collateral for a loan introduces a potential risk, as a significant price decline could trigger margin calls or forced sales, though it is subject to the Issuer's policy.

Risks

• Pledging of shares: Certain Reporting Persons have pledged interests exchangeable for 15,850,000 Class A Shares to secure a loan, which could lead to forced sales if the share price declines significantly and margin calls are not met.
• Vesting conditions: A portion of the Class E shares received by Mr. Legorreta are subject to vesting over five years and forfeiture if certain conditions (e.g., resignation without 'good reason', termination for cause, breach of restrictive covenants) are not met.

Future Outlook

The Reporting Persons acquired the securities for investment purposes and intend to continuously review their investments in Royalty Pharma plc. They may engage in discussions with management, the Board, other securityholders, and industry analysts. Mr. Legorreta, as CEO and Chairman, may influence corporate activities, including potential changes to the Board or management to increase shareholder value. The Reporting Persons reserve the right to change their investment purpose or formulate new plans at any time.

Management Comments

• Mr. Legorreta's business address is 110 East 59th Street, New York, NY 10022. He is the Chief Executive Officer of the Issuer, a director and the Chairman of the board of directors of the Issuer.
• Mr. Legorreta acquired the Class B Shares reported above for investment purposes in connection with the Transaction.
• Mr. Legorreta serves as the Chief Executive Officer of the Issuer and the Chairman of the Issuer's Board. In such capacity, Mr. Legorreta may have influence over the corporate activities of the Issuer, including activities that may relate to items described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.

Industry Context

This Schedule 13D filing primarily concerns changes in beneficial ownership by key insiders following a specific corporate transaction. It does not provide broad industry trends or competitive analysis, focusing instead on the internal ownership structure and related agreements of Royalty Pharma plc, a company specializing in royalty interests in pharmaceutical products.

Corporate Governance

Related Party Transactions

• The core transaction involves Royalty Pharma Holdings Ltd. (a subsidiary of the Issuer) acquiring equity interests from 'Sellers,' which include Pablo Legorreta, the Issuer's CEO and Chairman, and entities he controls (RP Management, LLC, RPM I, Holdings, LLC, RP MIP Holdings, LLC).
• Mr. Legorreta, as a seller, designated an entity wholly owned by him to receive Class B and Class E shares as consideration in the Transaction.
• The dissolution of the RP Management Equity Incentive Plan Trust, from which Mr. Legorreta received Class A Shares, also represents a related party dealing.

Stakeholder Impact

• Shareholders: The significant increase in beneficial ownership by the CEO and Chairman could be viewed positively as a sign of strong insider commitment and alignment of interests. However, the concentration of voting power (Mr. Legorreta has shared voting power over 95,303,291 shares) could also raise questions about corporate control.
• Employees: The transaction involved the issuance of Class E shares to certain employees, subject to vesting, which could impact employee retention and incentives. Mr. Legorreta also has a right to acquire forfeited Class E shares from other employees.

Next Steps

• Reporting Persons intend to review their investments in the Issuer on a continuing basis.
• Reporting Persons may engage in discussions with management, the Board, other securityholders, and industry analysts.
• Mr. Legorreta, in his capacity as CEO and Chairman, may influence corporate activities, including potential changes in the Board and/or management to increase shareholder value.
• An entity wholly owned by Mr. Legorreta has the right to acquire up to 857,136 Class E Shares from other employees if those securities do not vest and are forfeited.

Key Dates

Keywords

Royalty Pharma plc, Pablo Legorreta, Schedule 13D, Beneficial Ownership, SEC Filing, Class A Shares, Class B Shares, Class E Shares, Equity Acquisition, Insider Ownership, Corporate Governance, Share Pledging